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Background: Previous studies have demonstrated that induction of heme oxygenase-1 results in weight loss in
several rodent models of obesity. However, the specific role of the heme oxygenase-1 metabolite, carbon monoxide
(CO), in this response has yet to be established. We recently reported that chronic treatment with CO releasing
molecules results in prevention of weight gain in mice fed a high fat diet. In the present study, we sought to
determine the effect of chronic CO inhalation on the development and reversal of high fat diet induced obesity.
Results: CO inhalation at both levels initially resulted in a prevention and reversal of body weight and fat mass
over the first 10 weeks of treatment, however, this effect was not sustained. CO inhalation in the prevention groups
also had an early effect to lower fasting blood glucose but this effect also was not sustained.
Conclusions: Our results demonstrate that CO inhalation has a transient effect to prevent and reduce body weight
which is not sustained chronically in mice fed a high fat diet. These results suggest that chronic CO inhalation
therapy is not an effective treatment to induce long term weight loss.
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Despite a concerted effort to educate the public about the
problem of obesity, rates continue to increase worldwide.
As the problem of obesity expands so does the associated
condition of metabolic syndrome which is characterized
by insulin resistance, dyslipidemia, reduced HDL choles-
terol, and hypertension. These disorders increase the risk
for development of several metabolic and cardiovascular
diseases such as type II diabetes, coronary artery disease,
stroke, and end-stage renal disease [1,2]. Exploring poten-
tial treatment options for prevention and reversal of obes-
ity and its associated diseases is paramount to finding a
long term solution to this worldwide problem. Carbon
Monoxide (CO) is endogenously produced in the body via
the catabolism of heme by heme oxygenase (HO) enzymes
and by oxidation of lipids where it serves as a gaseous
transmitter [3-5]. HO enzymes exist in two major isoforms:
heme oxygenase-1 (HO-1) and heme oxygenase-2 (HO-2).* Correspondence: phosick@umc.edu
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unless otherwise stated.HO-1 is a 32 kilodalton protein which is inducible by a
wide variety of stimuli including oxidants, metals, and
hypoxia [6]. HO-2 is a 36 kilodalton protein which is
the constitutively expressed isoform important in vascular
function [7,8]. In addition to endogenously produced CO,
combustion of carbon compounds produces colorless
odorless CO gas. CO can be poisonous when levels greater
than 1500 parts per million (ppm) in the air are inhaled as
CO has a greater affinity for hemoglobin then does oxygen
ultimately resulting in severe tissue hypoxia.
Recent studies have demonstrated the beneficial actions
of chronic low dose CO inhalation for the prevention of
ischemic kidney injury and the lowering of blood pressure
[9-11]. Beneficial actions of CO inhalation were found in
the range between 20-250 ppm which are several fold
lower than the levels at which CO becomes poisonous.
Numerous studies have demonstrated that chemical in-
duction or genetic overexpression of HO-1 can attenuate
the development of obesity establishing a possible role of
endogenously produced CO to attenuate the development
of obesity [12-15]. While the HO-1 enzyme system has
been established to reduce weight gain in obesity the roleLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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role in obesity prevention. Recently our lab demonstrated
that chronic treatment with CO releasing molecules
(CORMs), which release CO independent of HO-1 induc-
tion, prevent the development of obesity in mice fed a
high fat diet [16]. Based upon our findings that chronic
treatment with CORMs attenuates weight gain in mice fed
a high fat diet, we sought to determine if CO inhalation
would have a similar effect as CORM injection in the
prevention of obesity in response to a high fat diet. In
the present study, 4 groups of mice on a high fat diet
were placed in a CO inhalation chamber daily for 30-
weeks to determine the specific effect of chronic CO




The experimental procedures and protocols of this study
conform to the National Institutes of Health Guide for the
Care and Use of Laboratory Animals and were approved
by the Institutional Animal Care and Use Committee of
the University of Mississippi Medical Center.
The ability of CO inhalation to either prevent or reverse
obesity was studied using separate groups exposed to 2
different concentrations of CO. CO inhalation was per-
formed in a specially designed chamber which allowed
mice to be exposed to different levels of CO without
leaving their home cages. Two different levels of CO
inhalation exposures were used in the present study.
Mice were exposed to CO at 28 parts per million (ppm)
for 2 hours daily (CO-28) or 200 ppm CO for 1 hour
daily (CO-200). All mice were housed under standard
conditions with full access to a 60% high fat diet (diet #
D12492, Research Diets, Inc., New Brunswick, NJ) and
water. Control mice were fed the high fat diet but did
not did not receive any CO exposure. For the preven-
tion study, a separate cohort of mice was maintained
on a 17% normal fat diet (Teklad 22/5 rodent diet,
#8640, Harland Laboratories, Inc., Indianapolis, IN).
CO inhalation
Mice were exposed to CO in a 25 × 27 × 38 cm clear
plastic chamber. A mixture of CO and air was flushed
through the chamber at a rate of 0.05–30 l/min. Pure
CO gas was mixed with appropriate amounts of air to
dilute the CO to the desired concentration in parts per
million (ppm), either ~28 or 200 ppm CO. A sampling
line was fed from the chamber and passed through a
Grey Wolf Indoor Air IQ-410 CO gas analyzer (Shelton,
CT) which was connected to a lap-top computer and
gave real time CO gas measurements using the Wolf-
Sense software package (Version 2011.28, Shelton, CT).
The CO concentration was verified using a handheldCO meter placed inside the inhalation chamber (C.E.,
China). This setup allowed for mice to be exposed to the
different levels of CO with free access to food and water
in their home cages throughout the daily treatment
periods. Mice were exposed to CO in the mornings for
2 hours in mice receiving 28 ppm CO and for 1 hour
in mice receiving 200 ppm.
Carboxyhemoglobin (COHb) measurement
Using a separate group of mice from those used in the
chronic CO inhalation studies; COHb was measured
before, immediately after and at 30, 60 and 90 minutes
following each CO inhalation exposure protocol. Blood
was collected via the orbital sinus under light isoflurane
anesthesia. Immediately after collection, the blood sample
was analyzed for COHb levels using Radiometer ABL80
Flex CO-OX analyzer (Westlake, OH) which requires
105 μl of whole blood. COHb levels are expressed as a
percentage of total hemoglobin.
Body composition (EchoMRI)
Body composition of all mice was assessed at 6 week
intervals throughout the study using magnetic reson-
ance imaging (EchoMRI-900TM, Echo Medical System,
Houston, TX). EchoMRI measurements were performed
in conscious mice placed in a thin-walled plastic cylinder
with a cylindrical plastic insert added to limit movement
of the mice. Mice were briefly submitted to a low intensity
electromagnetic field allowing both fat mass and lean mass
to be measured.
Fasting glucose
Following an overnight fast (~16 hours) a blood sample
was obtained under isoflorane anesthesia via orbital sinus.
Blood glucose was measured using an Accu-Chek Advan-
tage glucometer (Roche, Mannheim, Germany).
Oxygen consumption, carbon dioxide production and
motor activity. Twenty-eight weeks after the initiation
the experimental protocol 4 mice from each group
were placed individually in an acrylic cage (16 cm ×
24 cm × 17 cm) equipped with a metabolic monitoring
system (AccuScan system, Harvard Apparatus, Holliston,
Massachusetts) for measurements of oxygen consumption
(VO2), carbon dioxide production (VCO2) and respiratory
quotient (RQ) as previously described [15,16]. VO2, VCO2
and RQ were determined daily (for 2 min every 10-min
interval) and expressed as the 24 hour average. RQ was
calculated by the formula: VCO2/VO2. Motor activity was
determined using infrared light beams mounted in the
cages in x, y, and z axes. Heat production was derived
from the following formula (4.33 + (0.67*RQ)*VO2*weight
(g)*60). After the mice were acclimatized to the new envir-
onment for 1 day, VO2, VCO2, RQ and animal activity
were recorded for 2 consecutive days.
** *
200 ppm 1 hr (n=4)
20 ppm 2 hrs (n=4)
Figure 1 Carboxyhemoglobin percentage before and following
inhalation of CO at 200 ppm for 1 hr (n = 4) or 20 ppm for
2 hrs (n = 4). * = significant from pre value, p < 0.05.
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For glucose tolerance tests (GTT), mice were subjected to
an overnight fast (∼16 h) and intraperitoneal (IP) injection
of D-glucose (1 g/kg of body weight). Blood glucose was
monitored at 0, 15, 30, 60, and 90 min after glucose
injection using a portable glucose analyzer (Accu-Chek
Advantage glucometer, Roche, Mannheim, Germany).
Food consumption
Food consumption was measured at two time points,
early (10 weeks) and late (28 weeks) during the 30 weeks
of inhalation treatment. The total amount of food was
weighed daily in the morning for 5 consecutive days. The
daily consumption over the 5 day period was averaged for
each mouse to obtain 24-hour food consumption.
Western blot analysis
Western blots were performed on lysates prepared from
tissues collected at the end of the experiments. Samples
of 30 μg of protein were boiled in Laemmli sample buffer
(Bio-Rad, Hercules, CA) for 5 min and electrophoresed on
10 or 12.5% SDS-polyacrylamide gels and blotted onto
nitrocellulose membrane. Membranes were blocked with
Odyssey blocking buffer (LI-COR, Lincoln, NE) for 2 hours
at room temperature and then incubated with primary
antibodies overnight at 4°C. Membranes were incubated
with either Alex 680 (Molecular Probes) or IR Dye 800
(Rockland, Gilbertsville, PA) secondary antibodies for
1 hour at room temperature. Membranes were visualized
using an Odyssey infrared imager (Li-COR, Lincoln, NE)
which allows for the simultaneous detection of two
proteins. Densitometry analysis was performed using
Odyssey software (LI-COR, Lincoln, NE). Antibodies for
Western blots were as follows: aldehyde dehydrogenase-1
(ALDH1A1; Abcam, Cambridge, MA), HO-1 (Enzo Life
Sciences, Farmingdale, NY), nuclear receptor factor-1
(NRF-1; Rockland, Gilbertsville, PA), peroxisomal pro-
liferating activating receptor-γ coactivator (PGC1-α; Cell
Signaling Tech, Boston, MA), uncoupling protein-1 (UCP-
1; Sigma, St. Louis, MO) and β-actin (Abcam, Cambridge,
MA). All antibodies were used at a ratio of 1:1000 with
blocking buffer, the lone exception being β-actin which
was used at a ratio of 1:5000. All blots from tissue samples
were run in duplicate with 3 samples from each group
per gel with prevention reversal samples run on separ-
ate gels. These proteins were selected based upon our
previous study which demonstrated that these proteins
are regulated by CO [16].
Statistics
All data are presented as mean ± s.e.m. Differences be-
tween treatment groups were determined using one-way
analysis of variance with a post hoc test (Dunnett’s). A
P < 0.05 was considered to be significant. All analyseswere performed with SigmaStat (Systat software Inc.,
Richmond, CA, USA).
Results
Co inhalation and blood carboxyhemoglobin levels
The time course of CO inhalation on blood carboxy-
hemoglobin (COHb) levels in response to inhalation
of 28 or 200 ppm CO was examined in separate
groups of mice. CO inhalation of 28 ppm for 2 hours
resulted in significant doubling of blood COHb levels
which returned to baseline levels 60 min after being
removed from CO inhalation chamber (Figure 1). CO
inhalation of 200 ppm CO for 1 hour resulted in an in-
crease in blood COHb levels by 8 fold which were still
significantly elevated from baseline 60 min after inhalation
but returned to baseline levels by 90 min post inhalation
(Figure 1). These dissociation profiles are in agreement
with a previous study which examined the effects of high
levels (500 ppm) CO inhalation in mice [17].
Chronic CO inhalation transiently reduces body mass
and fat
In the obesity prevention groups, high fat diet resulted
in elevations in body weight by week 6 of treatment
compared to mice fed a normal 17% fat mouse chow
(Figure 2A). Both CO inhalation groups exhibited a re-
duction of body weight after 8 weeks of treatment which
remained until week 16 of treatment at which point body
weight was no different from control high fat diet mice
(Figure 2A). CO-28 mice had a significant reduction in
body weight as compared to control high fat mice at
weeks 23 and 24; however, body weight increased to
similar levels at week 25 and remained similar for the
duration of the study (Figure 2A). Body fat percentage
was significantly reduced in the normal diet control
prevention mice compared to all high fat diet mice at
all time points measured (Figure 2B). While body weight
was significantly reduced at 8 weeks into treatment in
the CO-28 mice, body fat percentage as measured by
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HF Control (n=7)
Figure 2 Effect of chronic CO inhalation on: (A) obesity prevention body weight measured weekly, (B) obesity prevention body fat
percentage as measured by echo-MRI, (C) obesity reversal body weight measured weekly, (D) obesity reversal body fat percentage as
measured by echo-MRI. * = significant from HF Control, p < 0.05. # = significant from all other groups, p < 0.05.
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into treatment (Figure 2B). At week 18 of the study,
body fat percentage was not different in the CO-28
mice; however, it was significantly reduced by 24 weeks
(Figure 2B). Surprisingly, body fat percentage was sig-
nificantly increased in the CO-28 mice as compared
to the other groups of high fat fed mice at week 30
(Figure 2B). Body fat percentage in the CO-200 treat-
ment group was significantly reduced compared to
the high fat control group at only week 6 of treatment
and then remained at similar levels for the duration
of the study (Figure 2B).
In the obesity reversal groups, both CO inhalation
groups exhibited a significant reversal of weight gain in
the first 5-10 weeks of treatment (Figure 2C). However,
this effect was lost after week 10 and their body weights
returned to similar levels as compared to the control high
fat diet group (Figure 2C). Body fat percentage was signifi-
cantly reduced in the CO-28 group at weeks 6 and 12 into
treatment; whereas, the CO-200 group was significantly
reduced at week 6 only (Figure 2D). There was no signifi-
cant difference in body fat mass between the groups for
the remainder of the obesity reversal study (Figure 2D).
Chronic CO inhalation transiently reduces blood
glucose levels
In the obesity prevention groups, both the CO-28 and
CO-200 groups had significantly reduced blood glucosecompared to the high fat diet control mice at 6 and
12 weeks into treatment but this effect was lost was lost
at 18, 24, and 30 weeks (Figure 3A). Normal diet control
mice had significantly reduced blood glucose levels from
all other groups at each time point measured (Figure 3A).
The CO-28 reversal obesity mice had significantly reduced
blood glucose level at 6 weeks, however; by week 24 these
mice had blood glucose levels significantly elevated com-
pared to control mice (Figure 3B). Fasted blood glucose of
the CO-200 mice was not different from the HFD control
mice at any time point measured (Figure 3B).
Chronic treatment with CO has no long term effect on
oxygen consumption, carbon dioxide production, motor
activity, heat production, or food intake
In obesity prevention groups, no significant differences
existed in VO2, VCO2, or Respiratory Exchange Ratio (RER)
between any of the groups (Table 1). Heat production was
greater in all HFD groups compared to normal diet con-
trols (p < 0.05) whereas motor activity was reduced in all
HFD groups compared to normal diets controls (p < 0.05)
(Table 1). Finally, the normal weight group had signifi-
cantly reduced food intake compared to the HF control
group at week 10 of the treatment (p < 0.05) (Table 1). In
the obesity reversal groups there was no significant differ-
ence between the groups with respect toward VO2, VCO2,
RER, heat production, motor activity, or food intake at





























































HF + 28 PPM CO (n=5)
HF + 200 PPM CO (n=4)
HF Control (n=7)
Figure 3 Effect of chronic CO inhalation on fasting blood glucose in the: (A) Prevention groups, (B) Reversal groups. * = significant from
HF Control, p < 0.05. # = significant from all other groups, p < 0.05.
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induced increase in HO-1 in epididymal adipose tissue
In obesity reversal groups, HO-1 in epididymal adipose
tissue was reduced by CO treatment: however, the reduc-
tion was only significant in the CO-200 mice (p < 0.05)
(Figure 4). In obesity prevention groups, all HFD groups
had increased HO-1 protein in epididymal adipose tissue
compared to the normal diet group (p < 0.05) (Figure 4).
Both CO inhalation groups had significantly reduced
HO-1 compared to the high fat diet group.
Chronic treatment with CO has differential effects on
markers of mitochondrial biogenesis in epididymal
adipose tissue
High fat diet reduced the marker of mitochondrial bio-
genesis NRF-1 (p < 0.05) in the prevention group. CO-28
treatment in the prevention groups had and additional
effect to reduce the level of NRF-1 (p < 0.05) (Figure 5).
The HFD Control group had a trend towards a reduc-Table 1 Average oxygen consumption (VO2), carbon dioxide




(n = 4) (n = 4) (n = 4)
VO2 (ml/kg/min) 54.2 ± 8.2 50.3 ± 8.1 55.6 ± 2.8
VCO2 (ml/kg/min) 40.3 ± 6.5 37.0 ± 7.3 40.7 ± 2.4
RER 0.73 ± 0.02 0.73 ± 0.04 0.73 ± 0.02
Heat Prod. (Cal/hr) 826 ± 135 797 ± 105 857 ± 43
Motor Act. (m/day) 3.88 ± 0.90 3.39 ± 0.56 4.44 ± 1.84
Food 10 weeks (g/day) 2.8 ± 0.1 2.5 ± 0.2 2.2 ± 0.1#
Food 28 weeks (g/day) 3.0 ± 0.2 3.0 ± 0.4 3.3 ± 0.8
Data are mean ± SD. *Significant from all HFD groups, p < 0.05. #Significant for normtion in the mitochondrial inhibitor ALDH1A1 (p = 0.065)
whereas there was no trend towards reduced ALDH1A1
in either CO inhalation group (Figure 5). In the obesity re-
versal groups, NRF-1 was reduced by CO-28 treatment
compared to both other groups (p < 0.05) (Figure 4).
Discussion
Induction of HO-1 has been demonstrated to prevent
the development of obesity in several rodent models
[12-15]. However, the specific role of its metabolite, CO,
in this response has not been established. We recently
reported that chronic treatment with a CO releasing
molecule, CORM-A1, prevented obesity in mice fed a high
fat diet by increasing O2 consumption, heat production,
and increased proteins in epididymal adipose tissue related
to browning of adipose tissue [16]. In that study, CORM-
A1 was administered by IP injection at a dose that does
not increase blood COHb levels [16]. In the present
study, we sought to determine if administration of COproduction (VCO2), respiratory exchange ratio (RER), heat
treatment and food consumption at week 28 of treatment
Reversal
Normal HFD HFD HFD
Control CO-28 CO-200 Control
(n = 4) (n = 4) (n = 4) (n = 4)
61.5 ± 5.7 56.5 ± 12.4 55.8 ± 8.8 52.7 ± 8.7
46.0 ± 4.4 41.2 ± 9.6 40.7 ± 6.5 39.1 ± 7.5
0.74 ± 0.02 0.73 ± 0.03 0.73 ± 0.01 0.74 ± 0.02
605 ± 68* 828 ± 168 912 ± 158 883 ± 84
8.87 ± 1.51* 4.52 ± 2.15 6.76 ± 3.24 3.77 ± 2.94
3.2 ± 0.8 3.7 ± 0.4 3.0 ± 0.1 3.2 ± 0.4
3.4 ± 0.3 3.2 ± 0.2 3.4 ± 0.3 3.2 ± 0.3
al diet control, p < 0.05.
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Figure 4 Representative Western blots from epidydmal fat tissues of chronic CO inhalation for the reversal of obesity from high fat
diet (HFD) control, HFD 28 ppm CO, HFD 200 ppm CO mice. A) Representative blots. B) Levels of HO-1. C) Levels of PGC1-α. D) Levels of
NRF1. E) Levels of ALDH1A1. * = significant from all other groups, p < 0.05. MWM=molecular weight marker.
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development and maintenance of high fat diet induced
obesity via alterations in O2 consumption, heat produc-
tion, and remodeling of epididymal adipose tissue. Our
results demonstrate that chronic inhalation of CO at
either 200 ppm for 1 hour a day or 28 ppm for 2 hours a
day resulted in a transient effect to prevent and reverse
the progression of obesity in mice fed a high fat diet. This
effect started at week 5 of treatment at lasted for 10 weeks
in the prevention and 5 weeks in the reversal mice. During
this time frame, mice in each treatment protocol exhibited
reduced body weights compared to control mice fed a
high fat diet despite eating similar amounts of food
(Table 1). Thus, the reduced body weight in the treatment
mice is not believed to be due to alterations in food con-
sumption or interruption of the circadian rhythm. During
this time frame, mice were protected against the develop-
ment of type II diabetes and also exhibited decreased body
fat percentage as compared to control mice fed the high
fat diet alone. Both the effects on fasting blood glucose
levels as well as body fat exhibited in mice receiving
CO inhalation were lost after a 10 week period in theprevention mice and a 5 week period in the reversal
mice. Interestingly, obesity prevention mice that received
the CO-28 treatment went on to exhibit a greater body fat
percentage following 30 of treatment as compared to the
other groups on the high fat diet. While the mechanism
responsible for the paradoxical nature of this chronic ef-
fect is not known, the level of CO exposure in the CO-28
mice is roughly equivalent to that found in cigarette
smoke and may be a mechanism by which chronic smok-
ing increases body weight. The paradoxical nature of CO-
28 inhalation on body weight in response to a high fat diet
needs to be examined in greater detail in future studies.
At present a full explanation for the transient nature of
the effect of CO inhalation on body weight in mice fed a
high fat diet is unknown. One potential explanation for
the early weight loss in response to CO inhalation could
be due to partial hypoxia especially in the mice receiving
200 ppm CO as this resulted in an 8 fold increase in blood
COHb levels. This response could be a similar to the effect
observed in sojourning to high altitudes and experiencing
weight loss [18]. This altitude response is widely believed















*=P<0.05 as compared to other groups =P<0.05 as compared to high fat control
HO-1
-Actin

























HFD 28 ppm CO (n=3)




































Figure 5 Representative Western blots from epidydmal fat tissues of chronic CO inhalation for the prevention of obesity from normal
fat control, high fat diet (HFD) control, HFD 28 ppm CO, HFD 200 ppm CO mice. A) Representative blots. B) Levels of HO-1. C) Levels of
PGC1-α. D) Levels of NRF1. E) Levels of ALDH1A1. * = significant from all other groups, p < 0.05. # = significant from HF Control mice, p < 0.05.
MWM=molecular weight marker.
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[19,20]. Several questions regarding the application of
this hypothesis to the early effect observed in our CO
inhalation groups exist. First, if hypoxic conditions were
causing the prevention and reversal of weight loss we
would have expected to see a more dramatic response in
the CO-200 mice. As these mice were experiencing a
greater level of hypoxia due to a more dramatic increase
in blood COHb levels; however, that was not the case, in
fact the opposite was true. Second, we measured food
intake early in the treatment period during the time when
the CO inhalation mice had significantly lower body
weights compared to control mice. At this point there was
no difference in food intake between any of the HFD
groups (Table 1). Since hypoxia mediated weight loss is
characterized by anorexic conditions, we do not believe
that hypoxia in the CO inhalation mice explains the tran-
sient effect of weight loss observed in the present study.
A lack of a long term effect could be explained by an
inability of CO to fully access adipose tissue and stimu-
late the browning of adipose tissue. This effect of CO on
visceral and epididymal adipose tissue was observed in
our previous study in which CORM-A1 was administeredchronically via IP injection [16]. The mechanism of CO
release into the tissue following inhalation is thought to be
the same as for oxygen except the affinity of hemoglobin
for CO is approximately 230 times that of oxygen. This
extremely high affinity of CO for hemoglobin is what
causes such severe hypoxia with CO poisoning. Once CO
becomes bound to hemoglobin it is difficult to remove;
thus, it may not be delivered to peripheral tissues, such as
adipose tissue, as effectively as CO released from CORMs
administered directly into the peritoneal cavity. It is
possible that inhaled CO, which became tightly bound
to hemoglobin, was circulated in the blood then became
dissociated and exhaled. If this occurs the majority of the
CO never would have reached the adipose tissue to func-
tion as an intracellular signaling molecule as would be
the case when injected or produced endogenously via the
HO enzyme system. Therefore, it is possible that the
CO inhalation did not have a lasting chronic effect be-
cause inhalation of the gas is not an ideal delivery
method to increase adipose CO levels chronically. The
results from our Western blot experiments would support
this hypothesis as no significant differences in markers
of increased oxidative metabolism were present in the
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possible that a different CO inhalation regimen might
result sustained weight loss. Zheng et al. recently reported
that CO inhalation at 250 ppm for 2 hours daily for
10 weeks resulted in significant weight loss, a decrease in
adiposity, and a decrease in food intake measured at the
end of the 10 week period [21]. This profile of weight
loss is in agreement with the initial weight loss that we
observed in our current study. However, whether CO
inhalation of 250 ppm for 2 hours daily results in a sus-
tained weight loss over a similar 30 week time frame was
not determined in that study [21]. Since CO inhalation of
250 ppm for 2 hours was associated with a decrease in
food intake when measured at 10 weeks, it is possible that
observed weight loss in this model is a result of hypoxia
induced anorexic conditions as previously mentioned. If
this were the case the results of Zheng et al. [21] would be
different from the observed weight loss in our current
study, as we did not detect any effect of CO inhalation on
food intake measured at either 10 or 28 weeks.
The mechanism responsible for the initial weight loss
in the CO inhalation groups is not known at the present
time. We did not perform any studies measuring O2
consumption, heat production, or activity at this early
time point. One potential mechanism for the initial
weight loss in the CO inhalation group is alteration in
the circadian rhythm due to placement in the inhalation
chambers. While this is a possibility, mice were placed
in the inhalation chambers at the same time each morn-
ing about 1 hour after daylight and they were exposed in
their home cages with free access to food and water. We
did measure food intake early on and did not find any
significant difference in the food intake of the any of
the groups of mice on a high fat diet suggesting that
alterations in food intake at this early time point does
not account for the differences in body weight observed
in the CO inhalation mice. The apparent trend for CO-
28 inhalation to have a greater effect to reduce weight
gain early on could possibly be due a greater effect on
mitochondrial biogenesis and remodeling of adipocytes
both of which could act to increase metabolism and
promote weight loss in these mice [16]. It is also possible
that this lower level of CO inhalation had a greater central
effect to stimulate metabolism through an unidentified
pathway; however, without any metabolic data specifically
from this early time period the effect of this level of CO
inhalation on metabolism is not known. At the end of the
30 week treatment period, we did not observe any changes
in proteins such as PGC-1α, NRF-1, and ALDH1A1 in the
mice inhaling CO suggesting that any effect CO inhalation
may have had on mitochondrial biogenesis or remodeling
of adipocytes was not sustained. Previous studies with the
central administration of the HO-1 inducer, cobalt proto-
porphyrin (CoPP), have demonstrated an initial decreasein body weight that was associated with a decrease in food
intake [22,23]. However, while food intake eventually
returns to normal levels, body weight is maintained at
lower level for weeks [22,23]. Thus, it is possible that in-
halation of CO may temporally reset an important central
signal eliciting initial weight loss. However, this effect is
not long lasting or is compensated for. The compensation
for initial weight loss in the mice receiving 28 ppm CO is
evident from the fact that these mice had significantly
greater body fat compared to the HFD control group at
30 weeks which cannot be explained by differences in
lean mass development, food intake or motor activity.
Compensation due to alterations in central signaling or
in the absorption of food in digestive track will need to
be explored in future studies in which more measurements
of metabolic state and hormones are made during the
initial weight loss period.Conclusions
Our results demonstrate that CO inhalation at 200 and
28 ppm has a transient effect to prevent and reverse
obesity. It is not likely that this effect is due to anorexic
conditions like that seen in response to high elevation
induced hypoxia as food intake was not altered by CO
inhalation. While the mechanism responsible for the initial
weight loss observed in the present study is not known,
our results indicate that chronic inhalation of CO does
not produce sustained weight loss. Other treatments to
chronically increase CO levels such as CORMs appear to
be more promising agents in the long term treatment of
obesity.
Abbreviations
ALDH1A1: Aldehyde dehydrogenase-1; CO: Carbon monoxide;
COHb: Carboxyhemoglobin; CORMs: Carbon monoxide releasing molecules;
CO-28: Carbon monoxide treatment at 28 ppm for 2 hour daily; CO-
200: Carbon monoxide treatment at 200 ppm for 1 hour daily; GTT: Glucose
tolerance test; HO-1: Heme oxygenase-1; IP: Intraperitoneal; NRF-1: Nuclear
respiratory factor-1; PGC-1α: Peroxisomal proliferating activating receptor-γ
cofactor α; ppm: Parts per million; RQ: Respiratory quotient; VCO2: Volume of
carbon dioxide; VO2: Volume of oxygen; kDa: Kilodaltons.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
PAH, JPG, and DES conceived and designed the study. PAH, EKA, MUG, and
DES collected and analyzed the data. PAH and DES performed statistical
analysis. PAH and DES drafted the manuscript. All authors edited and
approved the final version of the manuscript.
Acknowledgements
The authors would like to acknowledge the support of grants from the
National Heart, Lung and Blood Institute, PO1HL-51971, HL088421 (D.E.S.)
and 1T32HL105324 (P.A.H).
Received: 8 November 2013 Accepted: 21 February 2014
Published: 4 March 2014
Hosick et al. BMC Obesity 2014, 1:6 Page 9 of 9
http://www.biomedcentral.com/2052-9538/1/6References
1. Eckel RH, Grundy SM, Zimmet PZ: The metabolic syndrome. Lancet 2005,
365:1415–1428.
2. Hotamisligil GS: Inflammation and metabolic disorders. Nature 2006,
444:860–867.
3. Verma A, Hirsch DJ, Glatt CE, Ronnett GV, Snyder SH: Carbon monoxide: a
putative neural messenger. Science 1993, 259:381–384.
4. Johnson RA, Colombari E, Colombari DS, Lavesa M, Talman WT, Nasjletti A:
Role of endogenous carbon monoxide in central regulation of arterial
pressure. Hypertension 1997, 30:962–967.
5. Morse D, Sethi J, Choi AM: Carbon monoxide-dependent signaling.
Crit Care Med 2001, 30:S12–S17.
6. Abraham NG, Kappas A: Pharmacological and clinical aspects of heme
oxygenase. Pharmacol Rev 2008, 60:79–127.
7. Kaide JI, Zhang F, Wei Y, Jiang H, Yu C, Wang WH, Balazy M, Abraham NG,
Nasjletti A: Carbon monoxide of vascular origin attenuates the sensitivity of
renal arterial vessels to vasoconstrictors. J Clin Invest 2001, 107:1163–1171.
8. Parfenova H, Neff RA III, Alonso JS, Shlopov BV, Jamal CN, Sarkisova SA,
Leffler CW: Cerebral vascular endothelial heme oxygenase: expression,
localization, and activation by glutamate. Am J Physiol Cell Physiol 2001,
281:C1954–C1963.
9. Nakao A, Faleo G, Nalesnik MA, Seda-Neto J, Kohmoto J, Murase N:
Low-dose carbon monoxide inhibits progressive chronic allograft
nephropathy and restores renal allograft function. Am J Physiol Renal
Physiol 2009, 297:F19–F26.
10. Neto JS, Nakao A, Kimizuka K, Romanosky AJ, Stolz DB, Uchiyama T,
Nalesnik MA, Otterbein LE, Murase N: Protection of transplant-induced
renal ischemia-reperfusion injury with carbon monoxide. Am J Physiol
Renal Physiol 2004, 287:F979–F989.
11. Kobayashi A, Ishikawa K, Matsumoto H, Kimura S, Kamiyama Y, Maruyama Y:
Synergetic antioxidant and vasodilatory action of carbon monoxide in
angiotensin II - induced cardiac hypertrophy. Hypertension 2007,
50:1040–1048.
12. Peterson SJ, Drummond G, Kim DH, Li M, Kruger AL, Ikehara S, Abraham NG:
L-4 F treatment reduces adiposity, increases adiponectin levels, and
improves insulin sensitivity in obese mice. J Lipid Res 2008, 49:1658–1669.
13. Li M, Kim DH, Tsenovoy PL, Peterson SJ, Rezzani R, Rodella LF, Aronow WS,
Ikehara S, Abraham NG: Treatment of obese diabetic mice with a heme
oxygenase inducer reduces visceral and subcutaneous adiposity,
increases adiponectin levels, and improves insulin sensitivity and
glucose tolerance. Diabetes 2008, 57:1526–1535.
14. Burgess A, Li M, Vanella L, Kim DH, Rezzani R, Rodella L, Sodhi K, Canestraro M,
Martasek P, Peterson SJ, Kappas A, Abraham NG: Adipocyte heme oxygenase-
1 induction attenuates metabolic syndrome in both male and female obese
mice. Hypertension 2010, 56:1124–1130.
15. Csongradi E, Docarmo JM, Dubinion JH, Vera T, Stec DE: Chronic HO-1
induction with cobalt protoporphyrin (CoPP) treatment increases
oxygen consumption, activity, heat production and lowers body weight
in obese melanocortin-4 receptor-deficient mice. Int J Obes (Lond) 2012,
36:244–253.
16. Hosick PA, Alamodi AA, Storm MV, Gousset MU, Pruett BE, Gray W III, Stout J,
Stec DS: Chronic carbon monoxide treatment attenuates development of
obesity and remodels adipocytes in mice fed a high-fat diet. Int J Obes
(Lond) 2014, 38:132–139.
17. Wilson MR, O’Dea KP, Dorr AD, Yamamoto H, Goddard ME, Takata M:
Efficacy and safety of inhaled carbon monoxide during pulmonary
inflammation in mice. PLoS One 2010, 5:e11565.
18. Westerterp KR, Kayser B: Body mass regulation at altitude. Eur J
Gastroenterol Hepatol 2006, 18:1–3.
19. Kayser B: Nutrition and high altitude exposure. Int J Sports Med 1992,
13(Suppl 1):S129–S132.
20. Westerterp KR: Energy and water balance at high altitude. News Physiol Sci
2001, 16:134–137.
21. Zheng M, Zhang Q, Joe Y, Kim SK, Uddin MJ, Rhew H, Kim T, Ryster SW,
Chung HT: Carbon monoxide-releasing molecules reverse leptin resistance
induced by endoplasmic reticulum stress. Am J Physiol Endocrinol Metab
2013, 304:E780–E788.22. Galbraith RA, Kappas A: Intracerebroventricular administration of cobalt
protoporphyrin elicits prolonged weight reduction in rats. Am J Physiol
1991, 261:R1395–R1401.
23. Galbraith RA, Kow LM, Pfaff D, Kappas A: Injection of cobalt
protoporphyrin into the medial nuclei of the hypothalamus elicits
weight loss. Am J Physiol 1992, 263:R805–R812.
doi:10.1186/2052-9538-1-6
Cite this article as: Hosick et al.: Inhalation of carbon monoxide is
ineffective as a long-term therapy to reduce obesity in mice fed a high
fat diet. BMC Obesity 2014 1:6.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
